Intrinsiqq
Alto Neuroscience Inc. logo

Alto Neuroscience Inc.

ANRO

⊜ Compare

We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Through insig hts derived from our scalable and proprietary Precision Psychiatry Platform, or our Platform, we aim to discover brain-based biomarkers to better identify which patients are more likely to respon…

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$914M
EPS-$2.43
P/E-9.59
P/FCF-13.28
EV/EBITDA-7.83
FCF Yield–
Div. Yield–
Net Debt/FCF3.2x
Alto Neuroscience Inc. intrinsic value
52-Week Range
$11.13$36.64

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$84M

▼ -2.9% YoY

Op. Margin

–

ROIC

-34.26%

▲ +30.4pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$69M

▼ -4.6% YoY

Op. Cash Flow (TTM)

-$68M

▼ -9.2% YoY

Net Debt

-$223M

Net Cash Position

Cash & Equiv.

$244M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with ANRO

CompareIntrinsic value
INOInovio Pharmaceuticals, Inc.
$1.62-2.41%10
SPRBSpruce Biosciences Inc.
$46.61+8.88%10
ALTAltimmune, Inc.
$2.12+3.92%10
AZTRAzitra Inc.
$0.82-7.69%19
CNTBConnect Biopharma Holdings Ltd.
$0.78+0.90%10
XLOXilio Therapeutics, Inc.
$8.71+0.35%40
LQDALiquidia Corporation
$47.38+12.27%72
BOLTBolt Biotherapeutics Inc.
$6.54-0.46%25

Held by ETFs

ANRO is in 20 US ETFs. The largest of them, with ANRO's weight in each:

Alto Neuroscience (ANRO) in two numbers

Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-9.59
Negative: a loss over the last twelve months. Price to free cash flow -13.28.
Financials

Questions about Alto Neuroscience

Does Alto Neuroscience (ANRO) pay a dividend?

No. Alto Neuroscience (ANRO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 7 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in ANRO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ANRO

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.